UroGen Pharma Ltd. Increase (Decrease) in Accounts Receivable
UroGen Pharma Ltd. (URGN) reported Increase (Decrease) in Accounts Receivable of $55.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05
- UroGen Pharma Ltd. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $33.34M, a 303036.36% increase year-over-year.
- UroGen Pharma Ltd. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $22.33M.
- UroGen Pharma Ltd. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $13.38M.
- UroGen Pharma Ltd. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $54.00K, a 99.00% decline year-over-year.
- UroGen Pharma Ltd. increase (decrease) in accounts receivable for fiscal 2025 was $12.78M, a 163.02% increase from fiscal 2024.
- UroGen Pharma Ltd. increase (decrease) in accounts receivable for fiscal 2024 was $4.86M, a 77.40% increase from fiscal 2023.
- UroGen Pharma Ltd. increase (decrease) in accounts receivable for fiscal 2023 was $2.74M, a 177.51% increase from fiscal 2022.
- UroGen Pharma Ltd. increase (decrease) in accounts receivable for fiscal 2022 was $987.00K, a 78.87% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $33.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $55.67M 10-Q · filed 2026-08-05 | $69.05M derived: sum of 3 quarters · filed 2026-08-05 | $69.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $22.33M 10-Q · filed 2026-05-06 | $35.71M derived: sum of 2 quarters · filed 2026-05-06 | $35.76M derived: sum of 3 quarters · filed 2026-05-06 | $35.77M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $13.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $13.43M derived: sum of 2 quarters · filed 2026-03-02 | $13.44M derived: sum of 3 quarters · filed 2026-08-05 | $12.78M 10-K · filed 2026-03-02 |
| 2025-09-30 | $54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $65.00K derived: sum of 2 quarters · filed 2026-08-05 | -$599.00K 10-Q · filed 2025-11-06 | -$3.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$653.00K 10-Q · filed 2026-08-05 | -$3.15M derived: sum of 3 quarters · filed 2026-08-05 | $2.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$664.00K 10-Q · filed 2026-05-06 | -$3.16M derived: sum of 2 quarters · filed 2026-05-06 | $2.22M derived: sum of 3 quarters · filed 2026-05-06 | $5.48M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.89M derived: sum of 2 quarters · filed 2026-03-02 | $6.14M derived: sum of 3 quarters · filed 2026-03-02 | $4.86M 10-K · filed 2026-03-02 |
| 2024-09-30 | $5.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.64M derived: sum of 2 quarters · filed 2025-11-06 | $7.36M 10-Q · filed 2025-11-06 | $9.96M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.97M 10-Q · filed 2025-08-07 | $4.57M derived: sum of 3 quarters · filed 2025-08-07 | $1.91M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$1.28M 10-Q · filed 2025-05-12 | $1.31M derived: sum of 2 quarters · filed 2025-05-12 | -$1.35M derived: sum of 3 quarters · filed 2025-05-12 | $1.67M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$62.00K derived: sum of 2 quarters · filed 2025-03-10 | $2.95M derived: sum of 3 quarters · filed 2025-03-10 | $2.74M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $354.00K derived: sum of 2 quarters · filed 2024-11-06 | $143.00K 10-Q · filed 2024-11-06 | $3.42M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.80M 10-Q · filed 2024-08-13 | $6.08M derived: sum of 3 quarters · filed 2024-08-13 | $3.91M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$211.00K 10-Q · filed 2024-05-13 | $3.06M derived: sum of 2 quarters · filed 2024-05-13 | $898.00K derived: sum of 3 quarters · filed 2024-05-13 | $2.99M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.11M derived: sum of 2 quarters · filed 2024-03-14 | $3.21M derived: sum of 3 quarters · filed 2024-03-14 | $987.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | -$2.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$70.00K derived: sum of 2 quarters · filed 2023-11-14 | -$2.29M 10-Q · filed 2023-11-14 | $1.65M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$122.00K 10-Q · filed 2023-08-10 | $3.81M derived: sum of 3 quarters · filed 2023-08-10 | $2.08M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$2.22M 10-Q · filed 2023-05-11 | $1.72M derived: sum of 2 quarters · filed 2023-05-11 | -$12.00K derived: sum of 3 quarters · filed 2023-05-11 | $3.20M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $3.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $2.21M derived: sum of 2 quarters · filed 2023-03-24 | $5.42M derived: sum of 3 quarters · filed 2023-03-24 | $4.67M 10-K · filed 2023-03-24 |
| 2021-09-30 | -$1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.48M derived: sum of 2 quarters · filed 2022-11-10 | $737.00K 10-Q · filed 2022-11-10 | $4.97M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.46M 10-Q · filed 2022-08-11 | $6.70M derived: sum of 3 quarters · filed 2022-08-11 | $9.11M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$746.00K 10-Q · filed 2022-05-10 | $3.49M derived: sum of 2 quarters · filed 2022-05-10 | $5.90M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $4.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $6.64M derived: sum of 2 quarters · filed 2022-03-21 | $7.05M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $2.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $2.81M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $402.00K 10-Q · filed 2021-08-04 | |||
| 2018-09-30 | -$120.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $108.00K derived: sum of 2 quarters · filed 2019-11-12 | $112.00K 10-Q · filed 2019-11-12 | $78.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $228.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $232.00K 10-Q · filed 2019-08-09 | $198.00K derived: sum of 3 quarters · filed 2020-03-02 | $222.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $4.00K 10-Q · filed 2019-05-09 | -$30.00K derived: sum of 2 quarters · filed 2020-03-02 | -$6.00K derived: sum of 3 quarters · filed 2020-03-02 | -$18.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | -$34.00K derived: 10-K 12 month − 6-K 9 month · filed 2020-03-02 | -$10.00K derived: sum of 2 quarters · filed 2020-03-02 | -$22.00K derived: sum of 3 quarters · filed 2020-03-02 | -$83.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | $24.00K derived: 6-K 9 month − 6-K 6 month · filed 2018-11-13 | $12.00K derived: sum of 2 quarters · filed 2018-11-13 | -$49.00K 6-K · filed 2018-11-13 | |
| 2017-06-30 | -$12.00K derived: 6-K 6 month − 6-K 3 month · filed 2018-08-14 | -$73.00K 6-K · filed 2018-08-14 | ||
| 2017-03-31 | -$61.00K 6-K · filed 2018-05-15 | |||
| 2016-12-31 | $83.00K 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |